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Abstract 
Plexiform neurofibroma is a poorly circumscribed, diffuse enlargement of neural sheets that typically involves major nerve trunks of the 
head and neck region because of the rich innervations of this area. It is a benign tumor and is a virtually pathognomonic and often 
disabling feature of neurofibromatosis type 1 (NF-1 or Von Recklinghausen’s disease). We hereby report a case of facial neurofibroma in 
an adult female with neurofibromatosis type 1 (NF-1). 
 
Streszczenie 
Nerwiakowłókniak  splotowaty  to  słabo  odgraniczone,  rozlane  powiększenie  osłonek  nerwowych,  które  typowo  dotyczy  korzeni 
nerwowych  okolic  twarzy  i  szyi,  co  spowodowane  jest  ich  bogatym  unerwieniem.  Jest  to  guz  łagodny,  w  rzeczywistości 
patognomoniczny dla neurofibromatozy typu 1 (NF-1 lub choroba Von Recklinghausena), którego postać jest często traktowana jako 
cecha upośledzająca (zwł. wygląd pacjenta – przyp. redakcji). W tym artykule opisujemy przypadek nerwiakowłókniaka okolicy twarzy 
u dorosłej kobiety z NF-1. 
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Introduction 
Plexiform neurofibroma is a relatively common 
but  potentially  devastating  manifestation  of 
neurofibromatosis type 1 (NF-1). It is a poorly defined 
benign  tumor  of  the  peripheral  nerve  sheath  spreading 
out just under the skin or deeper in the body. The diffuse 
and  soft  nature  of  plexiform  neurofibroma  is  often 
compared to ‘a bag of worms’ and is to be distinguished 
from  a  vascular  malformation  or  a  lymphangioma. 
Plexiform  neurofibromas  are  locally  invasive,  non-
metastasizing,  and  generally  categorized  by  their 
location.  Tumors  of  head,  neck  and  face  are  the  most 
common, followed by lesions of the spine, extremities, 
mediastinum and abdomen [1]. 
Facial  plexiform  neurofibroma  may  produce  various 
degrees  of  cosmetic  and  functional  deformities  in  the 
head  and  neck  region.  Surgical  management  is  the 
mainstay  of  treatment,  but  within  the  head  and  neck 
region  it  is  limited  by  the  infiltrating  nature  of  these 
tumors, inherent operative morbidity and a high rate of 
regrowth. 
 
Case report 
A 45-year old unmarried female, normotensive, 
nondiabetic,  presented  to the out-patient department of 
our institute with a history of a swelling on the right side 
of her face especially over the right infraorbital region, 
right side of nose, adjacent right cheek, chin and jaw.The 
patient  reported  that  her  facial  disfiguring  growth  had 
started at birth and continuously increased in size since 
then. She had difficulty in speaking properly. She also 
complained of intermittent dull aching pain and itching 
on her face. There was no history of any regression in 
size   or  discharge from the swelling. The patient never 
noticed  any  similar  swelling  elsewhere  in  the  body. 
There was no history of trauma over the area. Also, there 
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was  no  history  suggestive  of  any  constitutional 
symptoms,  tingling  and  numbness  elsewhere  over  the 
body. There was no history of seizures, deafness, tinnitus 
or any other neurological deficit. The past medical and 
surgical  histories  were  unremarkable.There  was  no 
history of similar disease in any of the family members 
or first degree relatives. There was no known evidence of 
any  hereditary  disease  in  the  family  or  first  degree 
relatives. 
General physical examination revealed an averagely built 
adult  female  with  a  steady  gait,  and  satisfactory  vital 
signs  with  no  signs  of  pallor,  icterus,  cyanosis  or 
lymphadenopathy.  Systemic examination was also non-
contributory.  
Cutaneous examination revealed a large solitary swelling 
measuring approximately 6x5 cm in size with indistinct 
borders, overhanging on itself, present on the right side 
of face involving the right cheek, right side of upper lip, 
chin  and  right  jaw.  The  overlying  skin  showed 
hyperpigmentation  and  hypertrichosis  with  follicular 
prominence (Fig. 1,2). On palpation, there was no local 
rise in temperature or any tenderness. The swelling had a 
peculiar consistency, soft in most of the areas with few 
firm nodular areas, similar to that described in literature 
as a ‘bag of worms’. On auscultation, no bruit could be 
detected.  
 
     
Figure 1. Facial plexiform neurofibroma                  Figure 2. Facial plexiform neurofibroma (lateral view) 
  with hypertrichosis and follicular prominence   
     
  
Rest  of  the  cutaneous  examination  revealed  multiple 
hyperpigmented macules over her trunk and arms (Fig. 
3). These macules were sharply defined, ranging in size 
from a few mm to more than 3 cm in diameter and were 
more fifteen in number. Axillary and inguinal freckling 
(Crowe
,s  sign)  was  also  present.  There  were  also 
multiple  skin  coloured  papules  and  nodules distributed 
over trunk and upper limbs, ranging in size from a few 
mm to more than 3 cms in size.  
 
 
Figure 3. Cafe-au-lait macules and neurofibromas on 
trunk 
 
Slit lamp examination did not reveal any Lisch nodules. 
Fundus  examination  was  also  normal.  Routine 
haematological  and  biochemical  investigations  were 
normal.  Chest  X-ray,  skull  X-ray  and  X-ray  of  long 
bones did not reveal any abnormality. Ultrasonography 
of the abdomen was also normal. Craniospinal MRI did 
not reveal any abnormality. Excisional biopsy of ane of 
the  cutaneous  nodules  was  done  and  sent  for 
histopathological  analysis.  It  revealed  features  of 
neurofibroma. Based on the constellation of clinical and 
histological  features,  a  diagnosis  of    facial  plexiform 
neurofibroma  with  neurofibromatosis  type  1  was 
entertained. 
 
Discussion 
Neurofibromatosis type-1 (NF-1) is a common 
neurocutaneous  condition  with  an  autosomal  dominant 
inheritance. Descriptions of individuals reported to have 
neurofibromatosis have been discovered in manuscripts 
dating  from  1000  A.D  [2].  However,  it  was  not  until 
1881  that  Von  Recklinghausen  described 
neurofibromatosis  in  his  patients  Marie  Kientz  and 
Michael  Bar  [3].  His  colleagues  honoured  his 
contribution  by  naming  the  condition  as  Von 
Recklinghausen’s  disease.  However  the  different  forms 
of neurofibromatosis were not separated and delineated 
until the latter part of the twentieth century. At last eight 
forms  of  neurofibromatosis  have  been  recognized,  the 
most  common  form  being  NF-1,  or  Von 
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Recklinghausen’s disease. It accounts for about 90% of 
all the cases and is estimated to occur in one of every 
3000 births. There is no sex predilection. 
It  is  an  autosomal  dominant  disease  caused  by  a 
spectrum of mutations in the NF-1 gene. The NF-1 gene 
is located on the long arm of chromosome 17q 11.2 and 
encodes a 327 kDa protein called Neurofibromin [4]. The 
exact function of this protein is poorly understood, but 
the gene encoding neurofibromin has a sequence similar 
to a group of proteins called GTPase-activating proteins 
(GAP).  This  similarity  suggests  its  involvement  in 
negatively  regulating  the  proteins  coded  by  the  Ras 
oncogene [5].  
The Ras protein is like other G proteins and is dependent 
upon  GTP  binding  for  its  full  activity;  GAP  removes 
GTP  by  increasing  the  conversion  of  GTP  to  GDP. 
Enhanced Ras protein activity has been correlated with 
human  cancer  development,  and  dysfunction  of 
neurofibromin  could  contribute  to  this  [6].  Most  NF-1 
mutations result in reduced intracellular levels of the NF-
1  gene  product,  neurofibromin.  This  appears  to  be 
sufficient to cause most of the clinical manifestations of 
this disorder. 
A  consensus  development  conference  was  held  by  the 
National Institute of Health (NIH) in 1987 to establish 
diagnostic  criteria  of  patients  with  NF-1.  There  were 
seven diagnostic features recognized at this conference 
that have been applied without modification during the 
last 22 yrs. The diagnosis of NF-1 is established when 
two  or  more  of  these  seven  features  listed  below  are 
present [7]: 
·  Six or more Café-au-lait macules larger than 5 mm 
in  greatest  diameter  in  prepubertal  individuals:  15 
mm in greatest diameter in postpubertal individuals. 
·  Two  or  more  neurofibromas  of  any  type  or  one 
plexiform neurofibroma. 
·  Freckling in the axillary or inguinal regions. 
·  Optic glioma. 
·  Two or more Lisch nodules (iris hamartomas). 
·  A  distinctive  osseus  lesion  such  as  sphenoid 
dysplasia or thinning of the long bone cortex, with 
or without pseudoarthrosis. 
·  A first degree relative with NF-1 according to the 
above criteria. 
In our patient, three of the seven NIH diagnostic criteria 
were present. 
Plexiform  neurofibromas  are  benign  peripheral  nerve 
sheath tumours, often involving the trigeminal and upper 
cervical nerves [8]. They are diffuse, elongated fibromas, 
histologically similar to discrete neurofibromas and are 
usually seen in only 5-10 % of patients with NF-1. They 
often develop and become physically apparent within the 
first  2-5  years  of  life  [9].  Their  growth  rate  is  highly 
variable.  Often,  overlying  hyperpigmentation  (‘giant 
Café-au lait spot’) or hypertrichosis can be seen. 
There are two types of plexiform neurofibromas, nodular 
and  diffuse.  Diffuse  plexiform  neurofibroma  is  also 
known  as  elephantiasis  neurofibromatosa  and  is 
characterized  by  an  overgrowth  of  epidermal  and 
subcutaneous  tissue  associated  with  a  wrinkled  and 
pendulous appearance. They can arise anywhere along a 
nerve  and  have  poorly  defined  margins.  They  may 
appear on the face, legs, or spinal cord and frequently 
involve the cranial and upper cervical nerves. The cranial 
nerves  most  commonly  involved  in  plexiform 
neurofibromas are the fifth, ninth and tenth nerves [10]. 
They  can  be  quite  disfiguring  and  hemifacial 
hypertrophy can occur secondary to a plexiform tumor 
involvement  [11].  These  tumors  are  known  to  cause 
symptoms  ranging  from  minor  discomfort  to  extreme 
pain. The consistency of the lesion has been compared to 
thtat of ‘a bag of worms’ because of the presence of soft 
areas interspersed with firm nodular areas and this very 
consistency was well appreciable in the lesions seen in 
our  patient.  They  sometimes  show  vascular  nature 
causing dangerous bleeding and may complicate surgical 
procedure. There appears to be an increase in the size of 
these tumors during puberty and pregnancy [12]. About 
5% of the plexiform neurofibromas may turn malignant, 
usually into malignant peripheral nerve sheath tumors. 
On  microscopy,  plexiform  neurofibromas  have  a  loose 
myxoid background with a low cellularity. They consist 
of  poorly  organized  mixture  of  nerve  fibrils  with 
extensive  interlacing  of  the  nerve  tissue.  Small  axons 
may be seen among the proliferating Schwann cells and 
perineural  cells.  These  distorted  masses  are  still 
contained  within  perineurium  and  surrounded  by 
neurofibroma.  The  tumor  is  immunoreactive  for  S-100 
protein. 
The  management  of  patients  with  plexiform 
neurofibromas is not well defined and is aimed mostly at 
controlling symptoms. Surgical excision is probably the 
only  therapy  available  because  there  is  no  medication 
that  can  prevent  or  treat  plexiform  neurofibromas. 
However the results of surgical excisioin can be poor and 
the  procedures  can  be  complicated  due  to  the  size, 
location,  vascular  status,  neural  involvement, 
microscopic extension of the tumor, and the high rate of 
tumor regrowth. Tumors of the head / neck / face recur 
twice  as  compared  to  the  plexiform  neurofibromas  of 
other  locations.  Also,  subtotal  resections  recur  more 
frequently than total resection of tumors. Retinoic acid 
therapy, angiogenesis inhibitors (such as interferons and 
thalidomide)  are  alternative  therapies  to  surgery  that 
have  been  tried.  Oral  Farnesyl  protein  transferase 
inhibitors  and  cytokine  modulators  are  also  under 
investigation.  
The  disfiguring  nature  of  facial  plexiform 
neurofibromatosis  can  be  psychologically  traumatic  for 
most of the patients and often require good counseling. 
Psychological  counselling  with  instilling  of  self 
confidence  in  such  patients  can  possibly  reduce  their 
suffering and help them improve their quality of life. 
 
 
REFERENCES 
1.  Korf  BR:  Plexiform  neurofibromas.  Am  J  Med  Genet 
1999; 89: 31-37. 
2.  Zanca  A,  Zanca  A:  Antique  illustrations  of 
neurofibromatosis. Int J Dermatol 1980; 19: 55-58. 
3.  von  Recklinghausen  FD:  Ueber  die  multiplen  Fibrome 
der Haut and ihre Beziehung zu den multiplen Neuromen. 
Berlin: Hirschwald; 1882. 
© Our Dermatol Online 1.2012   27 
4.  Shen  MH,  Harper  PS,  Upadhyaya  M:  Molecular 
genetics  of  neurofibromatosis  type1  (NF  1).  J  Med 
Genet 1996; 33: 2-17. 
5. Wigler MH: Oncoproteins. GAP’s in understanding 
Ras. Nature 1990; 346: 696-697. 
6. Tsao H: Neurofibromatosis and tuberous sclerosis. 
In:  Bolognia  JL,  Jorizzo  JL,  Rapini  RP:  Editors: 
Dermatology. Vol 1. Edinburg: Mosby, 2003: P 853-
867. 
7. Neurofibromatosis: Conference statement. National 
Institute  of  Health  Consensus  Development 
Conference. Arch Neurol 1998; 45: 575-578. 
8.  Khachemoune  A,  Al  Aboud  K,  Al  Hawsawi  K: 
Diffuse plexiform neurofibroma in a 13 –year old girl. 
Dermatol Online J 2003; 9: 23. 
9.  Cunha  KS,  Barboza  EP,  Dias  EP,  Oliveria  FM: 
Neurofibromatosis  type  1  with  periodontal 
manifestation. A case report and literature review. Br 
Dent J 2005; 196: 457-602. 
10. D’ Ambrosio JA, Langlais RP, Young RS: Jaw and 
skull  changes  in  neurofibromatosis.  Oral  Surg  Oral 
Med Oral Pathol 1998; 66: 391-396. 
11. Neville BW, Damm DD, Allen CM, Bouquot JE: 
Oral  and  maxillofacial  pathology.  2
nd  ed-  Elsevier: 
Philadelphia; 2002. P. 457-461. 
12.  Frosch  MP,  Anthony  DC,  De  Girolami  UI:  The 
central  nervous  system.  In:  Kumar  V,  Abbas  AK, 
Fausto  N,  editors.  Robbins  and  Cotran.  Pathologic 
basis of disease. 7
th ed. Elsevier: Philadelphia; 2004. 
1412-1413.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Our Dermatol Online 1.2012 
Copyright by Iffat Hassan, et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 